MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors

Erik A. Lippa, Joel S. Schuman, Eve J. Higginbotham, Michael A. Kass, Robert N. Weinreb, Gregory L. Skuta, David L. Epstein, Blake Shaw, Daniel J. Holder, Deni A. Deasy, Jacob T. Wilensky

Research output: Contribution to journalArticle

68 Scopus citations

Abstract

Topical carbonic anhydrase inhibitors MK-507 and sezolamide hydrochloride (previously known as MK-417) were compared in a double-masked, randomized, placebo-controlled study in 82 patients with bilateral primary openangle glaucoma or ocular hypertension. MK-507 was given every 8 or 12, hours, sezolamide every 8 hours, or placebo every 8 or 12 hours for 4 days. Both drugs lowered intraocular pressure (IOP) substantially. MK-507 was somewhat more active than sezolamide, with a peak mean IOP reduction of 26.2% for MK-507 versus 22.5% for sezolamide, although the difference between the treatments was not statistically significant. These drugs may have potential in the treatment of glaucoma.

Original languageEnglish
Pages (from-to)308-313
Number of pages6
JournalOphthalmology
Volume98
Issue number3
DOIs
StatePublished - Jan 1 1991

Fingerprint Dive into the research topics of 'MK-507 versus Sezolamide: Comparative Efficacy of Two Topically Active Carbonic Anhydrase Inhibitors'. Together they form a unique fingerprint.

Cite this